×
S&P 500   3,892.59 (+1.24%)
DOW   31,323.49 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.60 (+1.88%)
MSFT   267.91 (+0.64%)
META   171.75 (+1.17%)
GOOGL   2,350.32 (+2.57%)
AMZN   116.08 (+1.53%)
TSLA   727.10 (+4.59%)
NVDA   157.54 (+4.12%)
NIO   22.34 (+7.25%)
BABA   123.60 (+3.76%)
AMD   79.12 (+5.00%)
MU   58.48 (+1.93%)
CGC   2.68 (+1.13%)
T   21.15 (+0.28%)
GE   62.33 (+1.23%)
F   11.56 (+4.52%)
DIS   97.18 (+1.14%)
AMC   13.73 (+9.23%)
PFE   53.11 (+0.68%)
PYPL   74.87 (+2.23%)
NFLX   189.80 (+3.12%)
S&P 500   3,892.59 (+1.24%)
DOW   31,323.49 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.60 (+1.88%)
MSFT   267.91 (+0.64%)
META   171.75 (+1.17%)
GOOGL   2,350.32 (+2.57%)
AMZN   116.08 (+1.53%)
TSLA   727.10 (+4.59%)
NVDA   157.54 (+4.12%)
NIO   22.34 (+7.25%)
BABA   123.60 (+3.76%)
AMD   79.12 (+5.00%)
MU   58.48 (+1.93%)
CGC   2.68 (+1.13%)
T   21.15 (+0.28%)
GE   62.33 (+1.23%)
F   11.56 (+4.52%)
DIS   97.18 (+1.14%)
AMC   13.73 (+9.23%)
PFE   53.11 (+0.68%)
PYPL   74.87 (+2.23%)
NFLX   189.80 (+3.12%)
S&P 500   3,892.59 (+1.24%)
DOW   31,323.49 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.60 (+1.88%)
MSFT   267.91 (+0.64%)
META   171.75 (+1.17%)
GOOGL   2,350.32 (+2.57%)
AMZN   116.08 (+1.53%)
TSLA   727.10 (+4.59%)
NVDA   157.54 (+4.12%)
NIO   22.34 (+7.25%)
BABA   123.60 (+3.76%)
AMD   79.12 (+5.00%)
MU   58.48 (+1.93%)
CGC   2.68 (+1.13%)
T   21.15 (+0.28%)
GE   62.33 (+1.23%)
F   11.56 (+4.52%)
DIS   97.18 (+1.14%)
AMC   13.73 (+9.23%)
PFE   53.11 (+0.68%)
PYPL   74.87 (+2.23%)
NFLX   189.80 (+3.12%)
S&P 500   3,892.59 (+1.24%)
DOW   31,323.49 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.60 (+1.88%)
MSFT   267.91 (+0.64%)
META   171.75 (+1.17%)
GOOGL   2,350.32 (+2.57%)
AMZN   116.08 (+1.53%)
TSLA   727.10 (+4.59%)
NVDA   157.54 (+4.12%)
NIO   22.34 (+7.25%)
BABA   123.60 (+3.76%)
AMD   79.12 (+5.00%)
MU   58.48 (+1.93%)
CGC   2.68 (+1.13%)
T   21.15 (+0.28%)
GE   62.33 (+1.23%)
F   11.56 (+4.52%)
DIS   97.18 (+1.14%)
AMC   13.73 (+9.23%)
PFE   53.11 (+0.68%)
PYPL   74.87 (+2.23%)
NFLX   189.80 (+3.12%)
NASDAQ:CNSP

CNS Pharmaceuticals News Headlines

$0.27
+0.01 (+4.23%)
(As of 07/7/2022 09:49 AM ET)
Add
Compare
Today's Range
$0.27
$0.27
50-Day Range
$0.26
$0.35
52-Week Range
$0.25
$1.98
Volume
12,200 shs
Average Volume
1.06 million shs
Market Capitalization
$10.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50
Get CNS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.

CNSP Media Mentions By Week

CNSP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CNSP
News Sentiment

1.43

0.77

Average
Medical
News Sentiment

CNSP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CNSP Articles
This Week

1

0

CNSP Articles
Average Week



CNSP Stock News Headlines Today

SourceHeadline
MarketBeat logoCNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Down 46.6% in June
americanbankingnews.com - July 1 at 6:18 AM
seekingalpha.com logoCNS Pharma rises 36% as U.S. FDA gives nod for deadly brain cancer therapy trial
seekingalpha.com - June 23 at 11:23 AM
finance.yahoo.com logoCNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
finance.yahoo.com - June 23 at 11:23 AM
MarketBeat logoCNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Significant Increase in Short Interest
americanbankingnews.com - June 15 at 5:24 AM
finance.yahoo.com logoCNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
finance.yahoo.com - June 8 at 8:56 AM
finance.yahoo.com logoCNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference
finance.yahoo.com - May 24 at 9:36 AM
finance.yahoo.com logoCNS Pharmaceuticals to Present at American Society of Clinical Oncology Meeting
finance.yahoo.com - May 19 at 9:31 PM
finance.yahoo.com logoCNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
finance.yahoo.com - May 18 at 10:14 AM
finance.yahoo.com logoCNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - May 16 at 10:19 AM
seekingalpha.com logoCNS Pharmaceuticals gets Spanish regulatory nod for brain cancer study
seekingalpha.com - April 28 at 12:19 PM
finance.yahoo.com logoCNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
finance.yahoo.com - April 28 at 12:19 PM
finance.yahoo.com logoCNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event
finance.yahoo.com - April 12 at 11:36 AM
seekingalpha.com logoCNS Pharmaceuticals gets French regulatory nod for brain cancer study
seekingalpha.com - April 8 at 4:38 AM
finance.yahoo.com logoCNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
finance.yahoo.com - April 6 at 8:58 AM
benzinga.com logoCNS Pharmaceuticals (NASDAQ: CNSP) CEO Shares Company Highlights At Virtual Growth Conference
benzinga.com - April 5 at 5:57 PM
baystreet.ca logoCNS Pharmaceutical Wins Approval From Swiss
baystreet.ca - April 5 at 12:41 PM
finance.yahoo.com logoCNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
finance.yahoo.com - March 23 at 10:20 AM
finance.yahoo.com logoCNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders
finance.yahoo.com - March 9 at 3:32 PM
benzinga.com logoCNS Pharmaceuticals Gives Corporate Presentation, Q&A Session
benzinga.com - March 8 at 6:52 PM
finance.yahoo.com logoCNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - March 3 at 5:33 PM
finance.yahoo.com logoWPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity
finance.yahoo.com - February 1 at 8:41 AM
finance.yahoo.com logoCNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
finance.yahoo.com - January 20 at 1:01 PM
finance.yahoo.com logoIs CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - January 20 at 1:01 PM
benzinga.com logoCNS Pharmaceuticals Closes on $11.5M Private Placement
benzinga.com - January 11 at 4:06 PM
finance.yahoo.com logoCNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
finance.yahoo.com - January 10 at 7:50 PM
seekingalpha.com logoCNS Pharmaceuticals to raise $11.5M in stock offering
seekingalpha.com - January 6 at 9:28 AM
finance.yahoo.com logoCNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
finance.yahoo.com - January 6 at 9:28 AM
finance.yahoo.com logo5 Beaten-Down Biotech Bets to Bounce Back in 2022
finance.yahoo.com - December 31 at 5:55 PM
nasdaq.com logoCns Pharmaceuticals Inc Shares Fall 4.7% Below Previous 52-Week Low - Market Mover
nasdaq.com - December 30 at 9:37 AM
finance.yahoo.com logoBears are Losing Control Over CNS Pharmaceuticals, Inc. (CNSP), Here's Why It's a 'Buy' Now
finance.yahoo.com - December 21 at 1:57 PM
benzinga.com logoCNS Pharmaceuticals Announces Committee Approval of Pivotal Berubicin Study
benzinga.com - December 6 at 12:31 AM
finance.yahoo.com logoCNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
finance.yahoo.com - December 2 at 8:59 AM
finance.yahoo.com logoCNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event
finance.yahoo.com - November 16 at 11:08 AM
finance.yahoo.com logoJTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
finance.yahoo.com - November 4 at 2:47 PM
uk.finance.yahoo.com logoCNS Pharmaceuticals, Inc. (CNSP)
uk.finance.yahoo.com - October 29 at 12:34 AM
finance.yahoo.com logoCNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme
finance.yahoo.com - October 11 at 8:56 AM
proactiveinvestors.com logoCNS Pharmaceuticals doses first group of patients to treat recurrent GBM in 'big moment'
proactiveinvestors.com - October 6 at 3:54 AM
proactiveinvestors.com logoCNS Pharmaceuticals doses first group of patients to treat recurrent GMB in 'big moment'
proactiveinvestors.com - October 4 at 6:04 PM
finance.yahoo.com logoCNS Pharmaceuticals Inc. Doses First Group of Patients in Potentially Pivotal Trial
finance.yahoo.com - September 30 at 4:24 PM
markets.businessinsider.com logoCNS Pharma Doses First Patient With Berubicin In Pivotal Study For Brain Cancer Treatment
markets.businessinsider.com - September 30 at 11:23 AM
finance.yahoo.com logoCNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)
finance.yahoo.com - September 30 at 11:23 AM
finance.yahoo.com logoCNS Pharmaceuticals (NASDAQ:CNSP) Will Have To Spend Its Cash Wisely
finance.yahoo.com - August 15 at 6:13 PM
finance.yahoo.com logoCNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook
finance.yahoo.com - August 13 at 5:49 PM
proactiveinvestors.com logoCNS Pharmaceuticals' FDA Fast Track brings it closer to 'move the needle towards approval'
proactiveinvestors.com - July 13 at 5:59 PM
finance.yahoo.com logoWPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
finance.yahoo.com - July 12 at 10:08 AM
marketwatch.com logoBioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin's Development
marketwatch.com - July 1 at 6:17 PM
finance.yahoo.com logoCNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM
finance.yahoo.com - July 1 at 1:17 PM
finance.yahoo.com logoWant to Buy CNS Pharmaceuticals (NASDAQ: CNSP) Stock? Read This First.
finance.yahoo.com - June 29 at 2:42 PM
markets.businessinsider.com logoFDA Grants Fast Track Designation To CNS's Berubicin For Glioblastoma Multiforme Treatment
markets.businessinsider.com - June 29 at 9:42 AM
marketwatch.com logoBioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP), WPD Pharmaceuticals to Soon Recruit Patients for Combined Berubicin Clinical Studies
marketwatch.com - June 29 at 9:42 AM
Get CNS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:CNSP) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.